Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm
- 5 February 2016
- journal article
- case report
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2132-2139
Abstract
Ipilimumab is a cytotoxic T-lymphocyte-associated antigen-4-blocking monoclonal antibody, which has shown a significant survival benefit in metastatic melanoma patients. Despite being a promising therapy for a disease with an otherwise rather dismal prognosis, it is associated with several immune-related adverse effects (IRAE) mainly targeted toward the digestive tract, skin, liver, and hypothalamic-pituitary axis. Ipilimumab-induced gastrointestinal toxicity (IGT) include diarrhea (~44 %), colitis (~18 %), bowel perforation (<1 %), and pancreatitis (<1.5 %). Early recognition of IRAE and treatment initiation are critical to decrease the risk of further complications. Management included steroids as initial therapy, followed by infliximab (anti-tumor necrosis factor alpha antibody) and/or surgical option for complications like bowel perforation. We present a series of three patients with metastatic melanoma, who received treatment with ipilimumab, and presented with varying gastrointestinal clinical manifestations and complications. Through this case series, our attempt is to make practicing gastroenterologists cognizant about the wide spectrum of gastrointestinal toxicity of this rather new clinical entity, as well as to discuss management algorithm for IGT.Keywords
This publication has 45 references indexed in Scilit:
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsJournal of Translational Medicine, 2013
- Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanomaCancer Management and Research, 2012
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic MelanomaClinical Cancer Research, 2012
- Steroid-Induced Sigmoid Diverticular Perforation in a Patient with Temporal Arteritis: A Rare Clinical PathologyClinical Medicine Insights: Pathology, 2012
- Colitis associated with biological agentsWorld Journal of Gastroenterology, 2012
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other TumorsCancer Biotherapy and Radiopharmaceuticals, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T CellsDigestive Diseases and Sciences, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006